Adaptimmune Therapeutics PLC
ADAPY· OTC
ADAPYAdaptimmune Therapeutics PLC
Filed Nov 2, 2017 · 10-Q · 33 days after period end · 0001104659-17-065442
| Metric | Q3 2017 | Q3 2016 | Q3 2015 |
|---|---|---|---|
| Revenue | $27.19M | $2.42M | $4.95M |
| Net Income | -$878.00K | -$18.49M | -$6.24M |
| EPS Diluted | $0.00 | -$0.04 | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR
ended Sep 30, 2017 · filed Nov 2, 2017 · 33 d after period end
